Atorvastatin downregulates plasma procarboxypeptidase U concentrations and improves fibrinolytic potential dose-dependently in hyperlipidemic individuals
Source
Journal of thrombosis and haemostasis - ISSN 1538-7933-21:5 (2023) p. 1266-1273
ProCPU is expressed by (primary) human monocytes and macrophages and expression differs between states of differentiation and activation
Source
International journal of molecular sciences - ISSN 1422-0067-24:4 (2023) p. 1-13
Activation of the carboxypeptidase U (CPU, TAFIa, CPB2) system in patients with SARS-CoV-2 infection could contribute to COVID-19 hypofibrinolytic state and disease severity prognosis
Source
Journal of Clinical Medicine - ISSN 2077-0383-11:6 (2022) p. 1-11
Pleiotropic effects of Atorvastatin result in a downregulation of the Carboxypeptidase U System (CPU, TAFIa, CPB2) in a mouse model of advanced atherosclerosis
Source
Pharmaceutics - ISSN 1999-4923-13:10 (2021) p.
Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis
Source
Journal of thrombosis and haemostasis - ISSN 1538-7933-17:6 (2019) p. 878-884